DEFM14A: Evofem Biosciences to Merge with Aditxt Inc.

Evofem Biosciences announced a special meeting of stockholders to vote on a merger agreement with Aditxt, Inc., with the transaction expected to close in the second half of 2025.

Summary

• Evofem Biosciences, Inc. is holding a special meeting of stockholders on September 26, 2025, to vote on a proposed merger with Aditxt, Inc.
• The merger agreement, dated July 12, 2024, involves Merger Sub, a subsidiary of Aditxt, merging with Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.
• Evofem common stockholders will receive cash consideration totaling $1,800,000, subject to adjustments for dissenting shares.
• Holders of Evofem Series E-1 and Series G-1 Convertible Preferred Stock will receive one share of Aditxt Preferred Stock for each share held.
• Company stock options will be extinguished and canceled at the Effective Time without consideration.
• The merger is expected to be completed in the second half of 2025, subject to various closing conditions, including stockholder approvals and regulatory clearances.
• Evofem's Board of Directors recommends a FOR vote on both the Merger Proposal and the Adjournment Proposal.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to Evofem's financial distress, the low merger consideration for common stockholders, and Aditxt's own going concern issues and Nasdaq delisting concerns, despite the strategic rationale for the combination.

Positives

• The merger provides cash consideration of approximately $0.015 per share for Evofem common stockholders, representing an approximate 65% premium to the closing price on August 22, 2025.
• The merger is expected to provide Evofem with greater resources to accelerate its growth trajectory as a subsidiary of Aditxt.
• Aditxt has provided $7.4 million in funding to Evofem since May 2024, enabling the acquisition of SOLOSEC and supporting initiatives for PHEXXI.
• Saundra Pelletier, Evofem's CEO, has been appointed to Aditxt's Board of Directors, indicating continued leadership involvement.

Negatives

• Evofem received Notices of Default from its largest creditor, Future Pak, LLC, who also terminated the forbearance agreement.
• The Company is required to stop using the PHEXXI name and trademark due to a settlement with TherapeuticsMD.
• Evofem's stock was delisted from Nasdaq in August 2022 and now trades on the OTCQB Venture Market, which may limit capital raising.
• Evofem's Phase 3 clinical trial for EVO100 did not meet its efficacy endpoints, impacting potential label expansion for PHEXXI.
• The merger consideration for common stockholders is cash only, meaning they will have no interest in the post-close entity unless they independently purchase Aditxt stock.
• Evofem did not seek an independent fairness opinion for the merger consideration, relying on its Board's assessment of fairness.
• Aditxt's financial situation raises substantial doubt about its ability to continue as a going concern, with over $9.7 million in accounts payable, approximately $5.7 million of which is over 90 days past due.

Risks

• Failure to complete the merger could negatively impact Evofem's stock price and future business and financial results.
• The Company may not be able to effect the merger pursuant to the Merger Agreement and could incur substantial costs.
• The announcement and pendency of the merger could cause disruptions in Evofem's business, which could have an adverse effect on its business and financial results.
• Certain provisions of the Merger Agreement may discourage third parties from submitting alternative acquisition proposals.
• Evofem and Aditxt may become involved in securities litigation or stockholder derivative litigation in connection with the Merger.
• The merger is subject to the consent of the Designated Agent, Future Pak, LLC, for the merger and its underlying transactions.
• Aditxt's ability to have its securities traded on the Nasdaq Capital Market is subject to meeting applicable listing criteria; delisting could adversely affect the value and liquidity of its common stock.

Future Outlook

The merger is expected to be completed in the second half of 2025, subject to the satisfaction of closing conditions, including stockholder approvals and regulatory approvals. Aditxt aims to bring stakeholders together to transform promising innovations into products and services that address challenging needs.

Management Comments

• We are asking for your support to further our mission of delivering innovation in women's healthcare and improving choices for women everywhere, with access to greater resources that can accelerate our growth trajectory as a subsidiary of Aditxt.
• The Evofem Board of Directors believes that, because of the financial skills and background of its members, it was qualified to conclude that the Merger is fair from a financial perspective to the Company's stockholders.

Industry Context

StockSavvy.ai notes that this merger reflects a trend of consolidation in the biopharmaceutical sector, particularly for companies focused on specialized areas like women's health, as they seek to gain scale and access to capital to navigate development and commercialization challenges.

Comparison to Industry Standards

• The $1.8 million cash consideration for Evofem common stockholders is a small total deal value compared to typical M&A transactions in the biopharmaceutical industry, suggesting a distressed sale or a strategic necessity for Evofem.
• Aditxt's financial condition, as indicated by its substantial net losses and working capital deficit, suggests that the merger may be more driven by Aditxt's need for Evofem's assets or market access rather than a premium valuation of Evofem's current business.

Management Changes

Legal Proceedings

• The Company has received several letters from purported Company stockholders demanding action regarding alleged omissions of material information in the preliminary proxy statement and for books and records related to the transaction and disclosures in the proxy statement. The Company believes these demands are without merit.

Related Party Transactions

• Saundra Pelletier, CEO and Member of the Board of Directors of Evofem, was appointed to the board of directors of Aditxt and concurrently serves on both boards since June 2025.
• Aditxt purchased Evofem Series F-1 Preferred Stock in multiple tranches as part of the merger consideration.
• Amro Albanna, Aditxt's CEO, and Shahrokh Shabahang, Aditxt's Chief Innovation Officer, have provided loans to Aditxt.

Stakeholder Impact

• Evofem stockholders will receive cash consideration for their common stock, with preferred stockholders receiving Aditxt Preferred Stock, and will no longer have an equity interest in Evofem.
• Evofem's officers and directors have interests in the merger that could differ from stockholders, including anticipated service in the Surviving Company and indemnification rights.
• The merger's completion is contingent on Aditxt securing sufficient financing, which could impact Aditxt's ability to meet its obligations and potentially affect its existing stockholders.

Next Steps

• Stockholders of Evofem Biosciences, Inc. are requested to vote on the Merger Proposal and the Adjournment Proposal.
• The merger is expected to close in the second half of 2025, subject to the satisfaction of closing conditions.

Key Dates

Recommendation

The merger offers a premium to Evofem's common stockholders, but the overall financial health of both companies and the significant risks associated with Aditxt's going concern status and Nasdaq compliance issues suggest a cautious approach. For Evofem stockholders, holding might be preferable to selling at current depressed prices, but the uncertainty surrounding Aditxt's future performance and the lack of equity in the combined entity for common stockholders warrants a 'hold' rather than a 'buy' recommendation.

Keywords

Evofem Biosciences, Aditxt, Merger Agreement, Special Meeting, Stockholder Vote, Proxy Statement, Business Combination, PHEXXI, SOLOSEC, Womens Health, Biopharmaceutical, SEC Filing, DEFM14A